131 related articles for article (PubMed ID: 35609158)
21. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.
Rüfenacht S; Gantenbein P; Boggian K; Flury D; Kern L; Dollenmaier G; Kohler P; Albrich WC
Infection; 2022 Jun; 50(3):783-790. PubMed ID: 35426564
[TBL] [Abstract][Full Text] [Related]
22. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.
Melander C; Sallée M; Trolliet P; Candon S; Belenfant X; Daugas E; Rémy P; Zarrouk V; Pillebout E; Jacquot C; Boffa JJ; Karras A; Masse V; Lesavre P; Elie C; Brocheriou I; Knebelmann B; Noël LH; Fakhouri F
Clin J Am Soc Nephrol; 2009 Mar; 4(3):579-87. PubMed ID: 19261822
[TBL] [Abstract][Full Text] [Related]
23. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.
Saleh MA
J Am Acad Dermatol; 2018 Jul; 79(1):97-103. PubMed ID: 29408700
[TBL] [Abstract][Full Text] [Related]
24. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
Alemany A; Millat-Martinez P; Corbacho-Monné M; Malchair P; Ouchi D; Ruiz-Comellas A; Ramírez-Morros A; Rodríguez Codina J; Amado Simon R; Videla S; Costes G; Capdevila-Jáuregui M; Torrano-Soler P; San José A; Bonet Papell G; Puig J; Otero A; Ruibal Suarez JC; Zarauza Pellejero A; Llopis Roca F; Rodriguez Cortez O; Garcia Garcia V; Vidal-Alaball J; Millan A; Contreras E; Grifols JR; Ancochea À; Galvan-Femenia I; Piccolo Ferreira F; Bonet M; Cantoni J; Prat N; Ara J; Forcada Arcarons A; Farré M; Pradenas E; Blanco J; Àngel Rodriguez-Arias M; Fernández Rivas G; Marks M; Bassat Q; Blanco I; Baro B; Clotet B; Mitjà O;
Lancet Respir Med; 2022 Mar; 10(3):278-288. PubMed ID: 35150610
[TBL] [Abstract][Full Text] [Related]
25. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
26. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.
Betrains A; Godinas L; Woei-A-Jin FJSH; Rosseels W; Van Herck Y; Lorent N; Dierickx D; Compernolle V; Meyfroidt G; Vanderbeke L; Vergote V; Lagrou K; Verhamme P; Wauters J; Vermeersch P; Devos T; Maes P; Vanderschueren S
Br J Haematol; 2021 Mar; 192(6):1100-1105. PubMed ID: 33314018
[No Abstract] [Full Text] [Related]
27. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival.
Jakubíková M; Týblová M; Tesař A; Horáková M; Vlažná D; Ryšánková I; Nováková I; Dolečková K; Dušek P; Piťha J; Voháňka S; Bednařík J
Eur J Neurol; 2021 Oct; 28(10):3418-3425. PubMed ID: 34080271
[TBL] [Abstract][Full Text] [Related]
28. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes.
Garrouste C; Canaud G; Büchler M; Rivalan J; Colosio C; Martinez F; Aniort J; Dudreuilh C; Pereira B; Caillard S; Philipponnet C; Anglicheau D; Heng AE
Transplantation; 2017 Mar; 101(3):649-656. PubMed ID: 27043407
[TBL] [Abstract][Full Text] [Related]
29. A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine: a case report and review of literature.
Honkila M; Niinimäki R; Taskinen M; Kuismin O; Kettunen K; Saarela J; Turunen S; Renko M; Tapiainen T
BMC Infect Dis; 2019 May; 19(1):404. PubMed ID: 31077135
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
31. Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed.
Daoussis D; Leonidou L; Kalogeropoulou C; Paliogianni F; Tzouvelekis A
Rheumatol Int; 2021 Oct; 41(10):1839-1843. PubMed ID: 34409510
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Front Immunol; 2021; 12():763412. PubMed ID: 34804051
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
[TBL] [Abstract][Full Text] [Related]
34. Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients.
Cheng DR; Barton R; Greenway A; Crawford NW
Expert Rev Vaccines; 2016 Dec; 15(12):1567-1574. PubMed ID: 27216827
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab.
Vasconcelos J; Portugal R; Torres R; Falcão S
BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34183316
[TBL] [Abstract][Full Text] [Related]
36. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
37. [The impact of immunosuppression and chronic kidney disease on immunogenicity of COVID-19 vaccines].
Windpessl M; Heine GH; Becker SL; Scheuer AL; Sester M; Kronbichler A
Dtsch Med Wochenschr; 2021 Oct; 146(19):1277-1282. PubMed ID: 34553353
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
39. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
40. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy.
Naeem S; Gohh R; Bayliss G; Cosgrove C; Farmakiotis D; Merhi B; Morrissey P; Osband A; Bailey JA; Sweeney J; Rogers R
Transpl Infect Dis; 2021 Feb; 23(1):e13451. PubMed ID: 32815238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
